Welcome to our dedicated page for Medical Care Technologies news (Ticker: MDCE), a resource for investors and traders seeking the latest updates and insights on Medical Care Technologies stock.
Medical Care Technologies Inc. develops and commercializes artificial intelligence applications across consumer software, imaging analysis, healthcare-oriented pre-screening and collectibles authentication. News about MDCE centers on its AI technology stack, including Snapshot Recipes, a mobile recipe application with AI-generated food and beverage content, and Real Game Used, a subsidiary developing a patent-pending AI authentication platform for sports memorabilia.
Company updates also cover AI imaging initiatives for dermatological analysis, wellness monitoring, product verification and automated quality control, as well as capital and asset-monetization activity through Infinite Auctions. Recurring announcements describe product redesigns, commercialization pathways, subsidiary activity, mobile-app user growth initiatives, and enterprise API or visual analytics use cases.
Medical Care Technologies (OTCID: MDCE) announced that its MDCE Melanoma Scan Beta platform is entering a new phase of testing by seeking its first volunteer cohorts to provide human-submitted skin images. This follows earlier development based on public dermatology datasets such as HAM10000, ISIC Archive collections, and TCIA melanoma cohorts.
According to the company, real-world user images are intended to introduce variability in lighting, devices, distance, skin tone, and image quality to better assess intake, workflow, body-map organization, and AI model performance. The beta-stage application is designed for image organization and longitudinal tracking, has no regulatory clearance, and is not intended for diagnosis or treatment.
Medical Care Technologies (OTC PINK:MDCE) reported further development of longitudinal body-map monitoring capabilities in its MDCE Melanoma Scan Beta app. The AI-assisted platform is being designed to help users organize, catalog, and track visible skin images over time using structured, repeatable imaging workflows and an interactive body-map interface.
The company is refining workflow, image consistency, usability, platform infrastructure, and AI vision for temporal image analysis, within a multi-phase internal testing process. The beta platform remains in development, has no regulatory clearance, and is positioned as an image organization and monitoring system for preventative wellness awareness rather than for diagnosis or treatment.
Medical Care Technologies (OTCID:MDCE) highlighted the cross-industry versatility of its StrainScan Pro AI vision platform, which uses a single computer-vision architecture for both regulated retail environments and large-scale agriculture. The software supports visual quality verification for licensed retailers and agricultural tasks such as early pest, crop-stress, and quality detection.
According to Medical Care Technologies, StrainScan Pro is optimized for deployment on iPad Air devices, giving both sectors a uniform, portable enterprise solution while allowing the company to advance one proprietary system. The company develops and commercializes AI vision software and does not handle cultivation or sale of plant products.
Medical Care Technologies (OTC PINK:MDCE) highlighted the enterprise-ready design of its StrainScan Pro AI vision platform, which uses a proprietary architecture optimized for rapid, straightforward deployment across multi-location retail and agricultural operations on iPad Air devices.
According to Medical Care Technologies, this tablet-based approach is intended to lower adoption barriers versus fixed industrial systems by standardizing the same software across fields, packing facilities, distribution environments, and retail sites. The company emphasized that it develops and commercializes AI vision software but does not cultivate, process, distribute, or sell cannabis or any plant products, and continues to generate revenue through operating subsidiaries.
Medical Care Technologies (OTC PINK: MDCE) reported further technical progress on its StrainScan Pro AI vision platform, emphasizing continuously learning computer-vision models designed to improve visual accuracy over time in both agricultural and regulated retail environments.
According to the company, StrainScan Pro refines performance as it processes more real-world visual data, enhancing identification of strain and quality characteristics for licensed operators and supporting detection of pests, crop stress, and quality indicators in agricultural settings. The software is optimized for deployment on iPad Air devices, preserving a portable enterprise form factor while the underlying AI models evolve. Medical Care Technologies stated that it develops and commercializes AI vision software, does not handle plant products, and is advancing AI capabilities across high-value verticals while generating revenue through operating subsidiaries.
Medical Care Technologies (OTC: MDCE) highlighted its StrainScan Pro platform as a scalable, enterprise AI vision solution for multi-location retail and agricultural operators. The proprietary software, optimized for deployment on iPad Air devices, supports visual strain and quality verification for licensed retail operators, early detection of pests and crop illness in the field, and freshness tracking concepts from harvest through distribution.
The company emphasized that it develops and commercializes AI vision software and does not handle cultivation or sale of plant products. StrainScan Pro targets multi-billion-dollar retail sectors and the global agriculture market, aligning with Medical Care Technologies’ broader AI vision strategy across high-value verticals.
Medical Care Technologies (OTCID:MDCE) highlighted the farm-to-plate capabilities of its proprietary AI vision platform StrainScan Pro, designed to provide rapid, on-device visual freshness and quality tracking across the food supply chain, from harvest and packing to distribution centers and retail environments.
According to the company, StrainScan Pro is optimized for deployment on iPad Air devices, enabling portable visual checks at critical handoff points. The platform is being advanced as a single tool to support quality verification across both regulated retail and broader agricultural networks. The company develops and commercializes AI vision software and states it does not cultivate, process, distribute, or sell cannabis or plant products.
Medical Care Technologies (OTCID:MDCE) highlighted the agricultural defense capabilities of its proprietary AI vision platform StrainScan Pro, designed for early detection of pests, crop illness, crop stress, and visual quality threats in the multi-trillion-dollar global agriculture sector. The system performs rapid, on-device visual analysis at the field, packing, or handling level.
According to the company, StrainScan Pro is optimized for deployment on iPad Air devices, providing a portable enterprise solution that does not require fixed industrial infrastructure. The platform is being advanced as a flexible tool for both regulated retail quality verification and large-scale agricultural monitoring. Medical Care Technologies continues to develop AI vision applications across multiple high-value verticals while generating revenue through its operating subsidiaries.
Medical Care Technologies (OTCID:MDCE) unveiled the strategic role of its StrainScan Pro platform, a proprietary AI vision solution aimed at enhancing visual quality verification in regulated cannabis retail and large-scale agriculture. The system provides rapid, on-device analysis to support strain consistency, potency-related visual indicators, and quality checks for licensed operators.
According to the company, the same computer-vision architecture targets broader agricultural needs such as early pest and crop-illness detection and identification of visual anomalies that may indicate bacterial or quality issues. Deployed on iPad Air devices, StrainScan Pro is intended for use across farms, packing facilities, distribution points, and retail locations, enabling freshness and quality tracking from field to final destination. Medical Care Technologies emphasizes that it develops and commercializes AI vision software and does not handle cannabis or plant products directly, while continuing to expand AI solutions across health, wellness, nutrition, lifestyle, and enterprise imaging.
Medical Care Technologies (OTC Pink: MDCE) is promoting its already-launched StrainScan Pro, an AI-powered computer-vision platform aimed at licensed, multi-location cannabis dispensary operators. The software provides rapid visual strain identification and quality verification and is specifically optimized for deployment on Apple iPad Air devices, enabling on-device analysis without fixed industrial systems.
According to the company, StrainScan Pro targets the multi-billion-dollar U.S. cannabis retail sector by offering mobile, scalable tools to support consistent operations across locations. Medical Care Technologies emphasizes that it develops AI vision technology and does not cultivate, process, distribute, or sell cannabis, and notes it also generates revenue through subsidiaries Infinite Auctions and Real Game Used.